博晖创新 reported revenue of ¥0.40B for the period ended 2026-06-30, -2.1% year on year. Net income was ¥-0.03B, a -7.4% net margin on a 32.8% gross margin. The largest revenue line is 人血白蛋白 at 31% of the total. Free cash flow for the period was ¥-0.02B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.40B | -2.1% |
| Gross profit | ¥0.13B | — |
| Operating income | ¥-0.03B | — |
| Net income | ¥-0.03B | — |
| Gross margin | 32.8% | Net margin -7.4% |
| Revenue Q/Q | +8.3% | — |
| Segment | Revenue | Share |
|---|---|---|
| 人血白蛋白 | ¥0.12B | 30.5% |
| 静注人免疫球蛋白 | ¥0.10B | 24.7% |
| 其他生物制品 | ¥0.08B | 20.3% |
| 质谱相关检测产品 | ¥0.03B | 8.2% |
| HPV检测产品 | ¥0.03B | 8.2% |
| 其他(补充) | ¥0.02B | 4.0% |
| 微量元素检测产品 | ¥0.01B | 3.3% |
| 其他检测相关产品及服务 | ¥0.00B | 0.7% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.27B | 67.2% |
| R&D | ¥0.03B | 6.6% |
| SG&A | ¥0.11B | 27.1% |
| Tax & other | ¥0.00B | 0.8% |
| Item | Amount |
|---|---|
| Total assets | ¥4.39B |
| Total liabilities | ¥2.24B |
| Shareholders' equity | ¥2.15B |
| Equity / assets | 48.9% |
| Operating cash flow | ¥0.00B |
| Capital expenditure | ¥0.03B |
| Free cash flow | ¥-0.02B |
| Cash conversion (OCF / net income) | 125% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
麦捷科技 ・ 海达股份 ・ 同大股份 ・ 硕贝德 ・ 华灿光电 ・ 旋极信息 ・ ST凯利 ・ 中颖电子 ・ 宜安科技 ・ 海伦钢琴 ・ 苏大维格 ・ 天壕能源
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies